Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of MaxCyte, Inc.’s cGMP compliant ExPERT GTx flow electroporation technology platform, marking it as the first Contract Development and Manufacturing Organization (CDMO) in China to be equipped with this advanced system.
The ExPERT GTx platform is renowned for its high transfection efficiency and cell viability, offering the flexibility to handle various transfection volumes while covering the entire workflow from research to clinical and cGMP production. This integration allows for seamless scaling up of large-scale preparations. Notably, MaxCyte’s technology has been instrumental in supporting the launch of the world’s first CRISPR/CAS9 gene editing therapy, Casgevy.
Porton Bio, already well-equipped with comprehensive cell therapy process facilities, has leveraged MaxCyto technology to provide Investigational New Drug (IND) product manufacturing, IND application support, and clinical project production services for a variety of cell therapy projects.- Flcube.com
